Cutaneous Immune-Related Adverse Events as Predictors of Pembrolizumab Efficacy: A Case Report of Complete Response in Metastatic Urothelial Cancer
1. Abstract Pembrolizumab is a PD-1 inhibitor widely used in various cancers, including urothelial carcinoma. While immune-related adverse events (irAEs) are known to indicate better response in some cancers, the role of skin lesions in predicting pembrolizumab efficacy remains unclear.